Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04546620
Title Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (REMoDL-A)
Acronym REMoDL-A
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Southampton NHS Foundation Trust
Age Groups: senior | child | adult
Covered Countries GBR

No variant requirements are available.